Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma

References

• Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, et al. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 3:409–17.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. 2000. Immunobiology of dendritic cells. Annu Rev Immunol. 18:767–811.
   PubMed Web of Science ®Google Scholar
• Bandola-Simon JM, Roche PA. 2019. Dendritic cells dysfunction in tumor-draining lymph nodes. J Immunol. 202:135–16.
   Web of Science ®Google Scholar
• Batty CJ, Tiet P, Bachelder EM, Ainslie KM. 2018. Drug delivery for cancer immunotherapy and vaccines. Pharm Nanotechnol. 6:232–44.
   PubMedGoogle Scholar
• Beningo KA, Wang Y. 2002. Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target. J Cell Sci. 115:849–56.
   PubMed Web of Science ®Google Scholar
• Brierley JD, Gospodarowicz MK, Wittekind C. 2017. UICC: TNM classification of malignant tumours. 8th ed. Oxford (UK): John Wiley & Sons, Inc.
   Google Scholar
• Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, et al. 2014. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 26:638–52.
   PubMed Web of Science ®Google Scholar
• Chamoto K, Chowdhury PS, Kumar A, Sonomura K, Matsuda F, Fagarasan S, Honjo T. 2017. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci U S A. 114:E761–E770.
   PubMed Web of Science ®Google Scholar
• Champion JA, Walker A, Mitragotri S. 2008. Role of particle size in phagocytosis of polymeric microspheres. Pharm Res. 25:1815–21.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang L, Yao Q, Ling R, Li K, Wang H. 2004. Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer. Breast Cancer Res. 6:R474–477.
   PubMed Web of Science ®Google Scholar
• Chowdhury D, Lieberman J. 2008. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol. 26:389–420.
   PubMed Web of Science ®Google Scholar
• Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R. 2006. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol. 6:659–70.
   PubMed Web of Science ®Google Scholar
• Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. 2002. IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol. 168:3195–204.
   PubMed Web of Science ®Google Scholar
• Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. 2000. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 60:3832–37.
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC. 2019. Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol. 19:89–103.
   PubMed Web of Science ®Google Scholar
• Fransen MF, Schoonderwoerd M, Knopf P, Camps MGM, Hawinkels LJAC, Kneilling M, van Hall T, Ossendorp F. 2018. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight. 3:e124507.
   PubMed Web of Science ®Google Scholar
• Gerber SA, Moran JP, Frelinger JG, Frelinger JA, Fenton BM, Lord EM. 2003. Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Br J Cancer. 88:1453–61.
   PubMed Web of Science ®Google Scholar
• Gray EE, Cyster JG. 2012. Lymph node macrophages. J Innate Immun. 4:424–36.
   PubMed Web of Science ®Google Scholar
• Hoon SB, Korn EL, Cochran AJ. 1987. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res. 47:1740–44.
   PubMed Web of Science ®Google Scholar
• Jones D, Pereira ER, Padera TP. 2018. Growth and immune evasion of lymph node metastasis. Front Oncol. 8:36.
   PubMed Web of Science ®Google Scholar
• Kataru RP, Ly CL, Shin J, Park HJ, Baik JE, Rehal S, Ortega S, Lyden D, Mehrara BJ. 2019. Tumor lymphatic function regulates tumor inflammatory and immunosuppressive microenvironments. Cancer Immunol Res. 7:1345–58.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. 1997. Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12. Blood. 90:2541–48.
   PubMed Web of Science ®Google Scholar
• Lieberman J. 2003. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol. 3:361–70.
   PubMed Web of Science ®Google Scholar
• Louie DAP, Liao S. 2019. Lymph node subcapsular sinus macrophages as the frontline of lymphatic immune defense. Font Immunol. 10:347.
   PubMed Web of Science ®Google Scholar
• Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. 2008. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 38:1404–13.
   PubMed Web of Science ®Google Scholar
• Matsuda T, Miyauchi E, Hsu YW, Nagayama S, Kiyotani K, Zewde M, Park JH, Kato T, Harada M, Matsui S, et al. 2019. TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. Oncoimmunology. 8:e1588085.
   PubMed Web of Science ®Google Scholar
• Mills BN, Connolly KA, Ye J, Murphy JD, Uccello TP, Han BJ, Zhao T, Drage MG, Murthy A, Qui H, et al. 2019. Stereotactic body radiation and interleukin-12 combination therapy eradicates pancreatic tumors by repolarizing the immune microenvironment. Cell Rep. 29:406–421.e5.
   PubMed Web of Science ®Google Scholar
• Molenkamp BG, van Leeuwen PA, Meijer S, Sluijter BJ, Wijnands PG, Baars A, van den Eertwegh AJ, Scheper RJ, de Gruijl TD. 2007. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res. 13:2961–69.
   PubMed Web of Science ®Google Scholar
• Moran I, Grootveld AK, Nguyen A, Phan TG. 2019. Subcapsular sinus macrophages: the seat of innate and adaptive memory in murine lymph nodes. Trends Immunol. 40:35–48.
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. 2006. The tumor-draining lymph node as an immune-privileged site. Immunol Rev. 213:146–58.
   PubMed Web of Science ®Google Scholar
• Nathanson SD, Shah R, Rosso K. 2015. Sentinel lymph node metastases in cancer: causes, detection and their role in disease progression. Semin Cell Dev Biol. 38:106–16.
   PubMed Web of Science ®Google Scholar
• Olszewski WL, Stanczyk M, Gewartowska M, Domaszewska-Szostek A, Durlik M. 2012. Lack of functioning intratumoral lymphatics in colon and pancreas cancer tissue. Lymphat Res Biol. 10:112–17.
   PubMed Web of Science ®Google Scholar
• Palomba R, Palange AL, Rizzuti IF, Ferreira M, Cervadoro A, Barbato MG, Canale C, Decuzzi P. 2018. Modulating phagocytic cell sequestration by tailoring nanoconstrct softness. ACS Nano. 12:1433–44.
   PubMed Web of Science ®Google Scholar
• Pan J, Zhang M, Wang J, Wang Q, Xia D, Sun W, Zhang L, Yu H, Liu Y, Cao X. 2004. Interferon-gamma is an autocrine mediator for dendritic cell maturation. Immunol Lett. 94:141–51.
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Hingorani SR. 2013. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer. 108:1–8.
   PubMed Web of Science ®Google Scholar
• Riley RS, June CH, Langer R, Mitchell MJ. 2019. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 18:175–96.
   PubMed Web of Science ®Google Scholar
• Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, Kaisho T, Bogunovic D, Bhardwaj N, Krummel MF. 2016. Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 30:324–36.
   PubMed Web of Science ®Google Scholar
• Rotman J, Koster BD, Jordanova ES, Heeren AM, de Gruijl TD. 2019. Unlocking the therapeutic potential of primary tumor-draining lymph nodes. Cancer Immunol Immunother. 68:1681–88.
   PubMed Web of Science ®Google Scholar
• Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N, et al. 2016. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 44:924–38.
   PubMed Web of Science ®Google Scholar
• Sharma A, Harper CM, Hammer L, Nair RE, Mathiowitz E, Egilmez NK. 2004. Characterization of cytokine-encapsulated controlled-release microsphere adjuvants. Cancer Biother Radiopharm. 19:764–69.
   PubMed Web of Science ®Google Scholar
• Sluijter BJR, van den Hout MFCM, Koster BD, van Leeuwen PAM, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, et al. 2015. Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3/CD141(+) dendritic cells and enhanced cross-presentation. Cancer Immunol Res. 3:495–505.
   PubMed Web of Science ®Google Scholar
• Swartz MA, Lund AW. 2012. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer. 12:210–19.
   PubMed Web of Science ®Google Scholar
• Tel J, Lambeck AJ, Cruz LJ, Tacken PJ, de Vries IJ, Figdor CG. 2010. Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol. 184:4276–83.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 13:251–76.
   PubMed Web of Science ®Google Scholar
• Tugues S, Burkhard S, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B. 2015. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 22:237–46.
   PubMed Web of Science ®Google Scholar
• Vuylsteke RJCLM, Molenkamp BG, Gietema HA, van Leeuwen P, Wijnands PGJTB, Vos W, van Diest PJ, Scheper RJ, Meijer S, de Gruijl TD. 2004. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res. 64:8456–60.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Deguchi K, Zheng R, Tamai H, Wang L, Cohen PA, Shu S. 2008. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol. 181:3291–300.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li N, Suh H, Irvine DJ. 2018. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat Commun. 9:6.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. 2014. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74:5057–69.
   PubMed Web of Science ®Google Scholar